



Please complete ALL information below and fax your request to 1-888-671-5285

Humatrope® Prior Authorization Request Form (Page 1 of 4)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required) Provider Information (required)

Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)

Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if generic substitution is acceptable		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)

Select the diagnosis below:

- Pediatric growth hormone deficiency
- Growth hormone deficiency in adults
- Growth hormone deficiency in transition phase adolescents
- Isolated growth hormone deficiency in adults
- Pediatric growth failure associated with chronic renal insufficiency
- Prader-Willi syndrome
- Short-stature homeobox (SHOX) gene deficiency
- Small for gestational age (SGA)
- Turner syndrome or Noonan syndrome
- Other diagnosis: _____ ICD-10 Code(s): _____

Clinical Information:

Is Humatrope prescribed by or in consultation with an endocrinologist? Yes No
 For patients with chronic renal insufficiency, is Humatrope prescribed by or in consultation with a nephrologist? Yes No
 Select if the patient has had a trial and failure or intolerance to the following:
 Norditropin
 Nutropin AQ/Nutropin AQ Nuspin
 Omnitrope

For pediatric growth hormone deficiency, also answer the following:

Is the patient an infant < 4 months of age? Yes No
 Does the infant have growth deficiency? Yes No
 Does the patient have history of neonatal hypoglycemia associated with pituitary disease? Yes No
 Does the patient have panhypopituitarism? Yes No
 Select if diagnosis of the pediatric GH deficiency is confirmed by the patient's height as documented by the following (utilizing age and gender growth charts related to height):
 Height > 2.0 standard deviations [SD] below mid-parental height
 Height > 2.25 SD below population mean (below the 1.2 percentile for age and gender)
 Is the patient's growth velocity > 2 SD below mean for age and gender? Yes No
 Does the patient have delayed skeletal maturation of > 2 SD below mean for age and gender (e.g., delayed > 2 years compared with chronological age)? Yes No

<continued on the next page>

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of FutureScripts. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**
 Office use only: Humatrope_FSP_2019Mar-W



Humatrope® Prior Authorization Request Form (Page 2 of 4)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

<continuation of pediatric growth hormone deficiency>

Is there documentation the patient's bone age is < 16 years for males or < 14 years for females? Yes No

Select if the patient has undergone provocative GH stimulation tests with the following: **(Document the GH response)**

- Arginine Peak value: _____mcg/L
- Clonidine Peak value: _____mcg/L
- Glucagon Peak value: _____mcg/L
- Insulin Peak value: _____mcg/L
- Levodopa Peak value: _____mcg/L
- Growth hormone releasing hormone Peak value: _____mcg/L

For patients less than 1 year of age, select if the following is below the age and gender adjusted normal range as provided by the physician's lab: **(Document the specified lab value and reference range)**

- Insulin-like growth factor 1 (IGF-1/Somatomedin-C) IGF-1/Somatomedin-C level: _____ Reference range: _____
- Insulin growth factor binding protein-3 (IGFBP-3) IGFBP-3 level: _____ Reference range: _____

Reauthorization:

Please document that the patient has had a height increase of at least 2 cm/year over the previous year of treatment below:

Previous height: _____ Date obtained: _____
Current height: _____ Date obtained: _____

Has the expected adult height been reached? Yes No

Document the expected adult height goal: _____

For growth hormone (GH) deficiency in adults, also answer the following:

Are there clinical records supporting a diagnosis of childhood-onset GH deficiency? Yes No

Does the patient have adult-onset GH deficiency? Yes No

Are there clinical records documenting that hormone deficiency is a result of hypothalamic-pituitary disease from organic or known causes (e.g., damage from surgery, cranial irradiation, head trauma, or subarachnoid hemorrhage)? Yes No

Select if the patient has undergone one of the following GH stimulation tests to confirm adult GH deficiency and the peak GH value is as follows:

- Insulin tolerance test (ITT) ≤ 5 mcg/L
- Arginine & GH-releasing hormone (GHRH+ARG) ≤ 11 mcg/L if body mass index (BMI) is < 25 kg/m²; ≤ 8 mcg/L if BMI is ≥ 25 and < 30 kg/m²; ≤ 4 mcg/L if BMI is ≥ 30 kg/m²
- Glucagon ≤ 3 mcg/L
- Arginine (ARG) ≤ 0.4 mcg/L

Select if there is documentation the patient has deficiency of the following anterior pituitary hormones:

- Adrenocorticotrophic hormone (ACTH) Prolactin
- Follicle-stimulating hormone/luteinizing hormone (FSH/LH) Thyroid stimulating hormone (TSH)

Does the patient have an IGF-1/Somatomedin-C level below the age and gender adjusted normal range as provided by the physician's lab? Yes No

Reauthorization:

Is there evidence of ongoing monitoring as demonstrated by documentation within the past 12 months of an IGF-1/Somatomedin-C level? Yes No

For isolated growth hormone deficiency in adults, also answer the following:

Is there documentation the patient has deficiency of GH defined by a failure to produce a peak serum GH level of > 5 mcg/L after provocative pharmacologic stimulation by two of the following tests: Insulin, L-arginine, and/or glucagon? Yes No

Reauthorization:

Is there evidence of ongoing monitoring as demonstrated by documentation within the past 12 months of an IGF-1/Somatomedin-C level? Yes No



Humatrope® Prior Authorization Request Form (Page 3 of 4)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

For growth hormone (GH) deficiency in transition phase adolescents, also answer the following:

Has the expected adult height been reached? Yes No

Are the patient's epiphyses closed on bone radiograph? Yes No

Select if there is documentation the patient has high risk of GH deficiency due to GH deficiency in childhood from one of the following:

- Embryopathic/congenital defects
- Irreversible structural hypothalamic-pituitary disease
- Genetic mutations
- Panhypopituitarism
- Deficiency of three or more of the following anterior pituitary hormones: ACTH, TSH, Prolactin, FSH/LH

Does the patient have an IGF-1/Somatomedin-C level below the age and gender adjusted normal range as provided by the physician's lab? Yes No

Is the patient at low risk of severe GH deficiency (e.g., due to isolated and/or idiopathic deficiency)? Yes No

Has GH therapy been discontinued for at least 1 month? Yes No

Select if the patient has undergone one of the following GH stimulation tests after discontinuation of therapy for at least 1 month and the peak GH value is as follows:

- Insulin tolerance test (ITT) ≤ 5 mcg/L
- Arginine & GH-releasing hormone (GHRH+ARG) ≤ 11 mcg/L if body mass index (BMI) is < 25 kg/m²; ≤ 8 mcg/L if BMI is ≥ 25 and < 30 kg/m²; ≤ 4 mcg/L if BMI is ≥ 30 kg/m²
- Glucagon ≤ 3 mcg/L
- Arginine (ARG) ≤ 0.4 mcg/L

Reauthorization:

Is there evidence the patient has had a positive response to therapy (e.g., increase in total lean body mass, exercise capacity or IGF-1 and IGFBP-3 levels)? Yes No

For pediatric growth failure associated with chronic renal insufficiency, also answer the following:

Is there documentation the patient's bone age is < 16 years for males or < 14 years for females? Yes No

Reauthorization:

Please document that the patient has had a height increase of at least 2 cm/year over the previous year of treatment below:

Previous height: _____ Date obtained: _____

Current height: _____ Date obtained: _____

Has the expected adult height been reached? Yes No

Document the expected adult height goal: _____

For Prader-Willi syndrome, also answer the following:

Reauthorization:

Is there evidence the patient has had a positive response to therapy (e.g., increase in total lean body mass, decrease in fat mass)? Yes No

Please document that the patient has had a height increase of at least 2 cm/year over the previous year of treatment below:

Previous height: _____ Date obtained: _____

Current height: _____ Date obtained: _____

Has the expected adult height been reached? Yes No

Document the expected adult height goal: _____

For short-stature homeobox (SHOX) gene deficiency, also answer the following:

Does the patient have a diagnosis of pediatric growth failure with short stature homeobox (SHOX) gene deficiency as confirmed by genetic testing? Yes No

Is there documentation the patient's bone age is < 16 years for males or < 14 years for females? Yes No

Reauthorization:

Please document that the patient has had a height increase of at least 2 cm/year over the previous year of treatment below:

Previous height: _____ Date obtained: _____

Current height: _____ Date obtained: _____

Has the expected adult height been reached? Yes No

Document the expected adult height goal: _____



Humatrope[®] Prior Authorization Request Form (Page 4 of 4)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

For small for gestational age (SGA), also answer the following:

Select if the diagnosis of SGA is based on demonstration of catch up growth failure in the first 24 months of life using a 0-36 month growth chart as confirmed by one of the following:

- Patient's **birth weight** was below the 3rd percentile for gestational age (> 2 SD below population mean)
- Patient's **birth length** was below the 3rd percentile for gestational age (> 2 SD below population mean)

Does patient's height remain \leq the 3rd percentile (> 2 SD below population mean)? Yes No

Reauthorization:

Please document that the patient has had a height increase of at least 2 cm/year over the previous year of treatment below:

Previous height: _____ Date obtained: _____

Current height: _____ Date obtained: _____

Has the expected adult height been reached? Yes No

Document the expected adult height goal: _____

For Turner syndrome (gonadal dysgenesis) or Noonan syndrome, also answer the following:

Is there documentation the patient's bone age is < 16 years for males or < 14 years for females? Yes No

Is the patient's height below the 5th percentile on growth charts for age and gender? Yes No

Reauthorization:

Please document that the patient has had a height increase of at least 2 cm/year over the previous year of treatment below:

Previous height: _____ Date obtained: _____

Current height: _____ Date obtained: _____

Has the expected adult height been reached? Yes No

Document the expected adult height goal: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.